| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Interim CEO, COO & CFO | COO & Chief Financial Officer
2 companies
Christopher P. Lowe last filed a Form 4 in August 2022, as Interim CEO, COO & CFO at QNCX. The filings on record cover 2 companies. Christopher P. Lowe's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Christopher P. Lowe's trades have earned a strong insider score of 77/100 across 3 rated trades. Over a 12-month horizon, all 3 of those trades were profitable, with an average 12-month return of +97.4%.
At the last filing, the largest reported position was 265,000 shares of QNCX. The QNCX filings lean toward selling, a net 46,963 shares.
Christopher P. Lowe has 15 Form 4 filings on record from February 2020 to August 2022, across 2 companies: Director at Vincerx Pharma (VINC), 2020–2022; Interim CEO, COO & CFO at Quince Therapeutics (QNCX), 2020–2022.
The 30 reported transactions were 10 open-market sales, 9 option or other derivative awards, 6 option exercises and 4 open-market purchases, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 2 purchases worth about $176K and 3 sales worth about $3.7M.
The largest open-market purchase was 10,000 shares of VINC at an average $12.62 on June 30, 2021, about $126K.
The largest open-market sale was 22,000 shares of QNCX at an average $95.31 on August 16, 2021, about $2.1M. Twelve months later QNCX was down 98%.
Shares as reported in the last Form 4 for each company; the most recent is from August 2022. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 25, 2022 | VINC Vincerx Pharma, Inc. | Director | Buy | 30,000 | $1.65 | $49,438.12 | +300.0% | - | - | |
| Oct 5, 2021 | QNCX Quince Therapeutics, Inc. | COO & Chief Financial Officer | Sale+OE | 4,963 | $98.50 | $488,855.50 | -7.6% | -86.2% | -98.7% | |
| Aug 16, 2021 | QNCX Quince Therapeutics, Inc. | COO & Chief Financial Officer | Sale+OE | 22,000 | $95.31 | $2,096,778.94 | -42.3% | -84.4% | -97.7% | |
| Jun 30, 2021 | VINC Vincerx Pharma, Inc. | Director | Buy | 10,000 | $12.62 | $126,152.00 | New | - | - | |
| Jun 28, 2021 | QNCX Quince Therapeutics, Inc. | COO & Chief Financial Officer | Sale+OE | 20,000 | $54.15 | $1,083,073.50 | - | +72.2% | -95.8% |